Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Reuters
01/08
Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Humacyte Inc. announced the results of a five-year retrospective analysis examining hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. The study found that the average hospital charge for initial extremity arterial injury repair was $316,600 per patient. Preventable complications, such as amputation and conduit infection, increased hospital charges by approximately $493,000 and $590,000 per patient, respectively. The analysis also indicated that Humacyte’s Symvess, an acellular tissue engineered vessel, demonstrated low rates of infection and high rates of limb salvage. All data were collected prior to FDA approval of Symvess and reflect healthcare economics before its commercialization. The results have already been announced by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621911) on January 08, 2026, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10